Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823726 | 0.78 | — | — | |
| SCHEMBL826060 | 0.75 | — | — | |
| SCHEMBL10719930 | 0.72 | MAPT (0.49) | KMT2AMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL14193571 | 0.70 | MAPT (0.47) | KMT2AMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL10047902 | 0.70 | MAPT (0.48) | KMT2AMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL10038918 | 0.69 | KMT2A (0.49) | KMT2AMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2683601 | 0.69 | MAPT (0.46) | KMT2AMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL17662406 | 0.68 | RIPK1 (0.41) | KMT2AMAPTCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL5051388 | 0.68 | MAPT (0.45) | KMT2AMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL10047911 | 0.67 | KMT2A (1.00) | KMT2AMAPTALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017175238-A1 | HIGHLY CHEMOSELECTIVE REACTIONS IN PRESENCE OF AROMATIC AMINO GROUPS | NEON LABORATORIES LIMITED (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2016050209-A1 | HETEROFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE, PREPARATION METHOD, AND BIO-RELATED SUBSTANCE | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8168647-B2 | Vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-05-01 | — | — | US | disclosed |
| US-8168647-B2 | Vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-05-01 | — | — | US | disclosed |
| US-8168647-B2 | Vinblastine derivatives, their preparation, use and pharmaceutical compositions comprising the said derivatives | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-05-01 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| WO-2007030361-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-6391916-B1 | ANTITUMOR AGENTS | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2002-05-21 | — | — | US | disclosed |
| US-5527805-A | DNA-CLEAVING, CYTOTOXIC AND ANTI-TUMOR COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-06-18 | — | — | US | disclosed |
| US-5434274-A | Benz(epsilon)indene compounds | WASHINGTON UNIVERSITY (US) | 1995-07-18 | — | — | US | disclosed |
| US-5281710-A | Antibiotics or antitumor agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-25 | — | — | US | disclosed |
| US-5276159-A | Antitumor | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | KMT2A 2733/4885MAPT 1126/4885ALDH1A1 1060/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | KMT2A 216/4885MAPT 2593/4885ALDH1A1 2275/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | KMT2A 455/4885MAPT 3856/4885ALDH1A1 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.